These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38626633)

  • 21. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
    McKean MA; Amaria RN
    Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
    Arak H; Erkiliç S; Yaslikaya Ş; Eylemer Mocan E; Aktaş G; Özdemir M; Semiz HS; Kiliçkap S; Özalp FR; Sever ÖN; Akdağ G; Ağaoğlu AB; Özçelik M; Sari M; Arcagök M; Anik H; Yayla ŞB; Sever N; Açar FP; Bayrakçi İ; Turhal S; Ayhan M; Kuş T;
    J Immunother; 2024 Jun; 47(5):182-189. PubMed ID: 38333962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human CD141
    Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant systemic therapy in high-risk melanoma.
    Blankenstein SA; van Akkooi ACJ
    Melanoma Res; 2019 Aug; 29(4):358-364. PubMed ID: 30896556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
    Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Bhave P; Pallan L; Long GV; Menzies AM; Atkinson V; Cohen JV; Sullivan RJ; Chiarion-Sileni V; Nyakas M; Kahler K; Hauschild A; Plummer R; Trojaniello C; Ascierto PA; Zimmer L; Schadendorf D; Allayous C; Lebbe C; Maurichi A; Santinami M; Roy S; Robert C; Lesimple T; Patel S; Versluis JM; Blank CU; Khattak A; Van der Westhuizen A; Carlino MS; Shackleton M; Haydon A
    Br J Cancer; 2021 Feb; 124(3):574-580. PubMed ID: 33087895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.
    Mueller KL; Theoret MR; Lemery SJ; Amiri-Kordestani L; Ariyan CE; Atkins MB; Berry DA; Blank CU; DeMichele AM; Forde PM; Ibrahim N; Keegan P; Mitchell TC; Moss RA; Robert C; Sridhara R; Taube JM; Tetzlaff MT; Wargo JA; Flaherty KT; Kaplan MJ; Topalian SL; Ward AF; Hurlbert MS
    Clin Cancer Res; 2021 Jan; 27(2):394-401. PubMed ID: 33188142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
    Haugh A; Daud AI
    Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant therapy for high-risk bulky regional melanoma.
    Tarhini AA; Pahuja S; Kirkwood JM
    J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous melanoma and the immunotherapy revolution (Review).
    Leonardi GC; Candido S; Falzone L; Spandidos DA; Libra M
    Int J Oncol; 2020 Sep; 57(3):609-618. PubMed ID: 32582963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies.
    Wang R; Chen Y; Xie Y; Ma X; Liu Y
    Int Immunopharmacol; 2024 May; 132():111989. PubMed ID: 38583243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.
    Rafei-Shamsabadi D; Lehr S; von Bubnoff D; Meiss F
    Cancer Immunol Immunother; 2019 Sep; 68(9):1417-1428. PubMed ID: 31422446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
    Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conjunctival Melanoma: Current Treatments and Future Options.
    Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
    Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
    Lau PK; Ascierto PA; McArthur G
    Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
    Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
    J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitors in melanoma.
    Carlino MS; Larkin J; Long GV
    Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
    Maio M; Blank C; Necchi A; Di Giacomo AM; Ibrahim R; Lahn M; Fox BA; Bell RB; Tortora G; Eggermont AMM
    Eur J Cancer; 2021 Jul; 152():155-164. PubMed ID: 34107449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.